Senior Administration officials recently met with the CEOs of Sanofi, AstraZeneca, and Thermo Fisher Scientific to discuss the importance of increasing the availability of RSV immunizations for infants. The officials emphasized the need to work urgently to meet demand during this viral season. The meeting follows previous engagements with manufacturers, which resulted in an additional 230,000 doses of RSV immunizations for infants being made available in January. This is in addition to the 77,000 doses that were released in November. The officials and CEOs also agreed on the significance of ongoing communication for planning the next respiratory viral season in 2024-2025.